FcγR expression on various cell types in SCD patients. (A) FcγRIIc expression on natural killer (NK) cells of patients expressing FCGR2C.nc-ORF variant (n = 6), FCGR2C-stop variant (n = 7), and FCGR2C-ORF variant (n = 2). In red, NK cells of healthy controls with the FCGR2C-ORF variant (n = 4). (B) FcγRIIb/c expression on neutrophils, monocytes, B cells, T cells, and NK cells on patient cells expressing the FCGR2C.nc-ORF variant (n = 6), FCGR2C-stop variant (n = 8), and FCGR2C-ORF variant (n = 2). (C) FcγRIIa expression on neutrophils, monocytes, B cells, T cells and NK cells on patient cells expressing the FCGR2C.nc-ORF variant (n = 4), FCGR2C-stop variant (n = 5), and FCGR2C-ORF variant (n = 2). (D) FcγRIIIa/b expression on neutrophils, monocytes, B cells, T cells, and NK cells on patient cells expressing the FCGR2C.nc-ORF variant (n = 6), FCGR2C-stop variant (n = 9), and FCGR2C-ORF variant (n = 2). Error bars denote the standard errors of the mean. Stars represent highly significant differences. ***P < .001; ****P < .0001. NK, natural killer; ns, nonsignificant differences.